Stock of the Day

Today's Trend

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares fell sharply after the company reported disappointing Phase 3 endometrial-cancer results. The news prompted an unusually heavy trading volume and a series of analyst target-price reductions, although the company’s myelofibrosis program provides a potential catalyst.

• Karyopharm plans to submit a supplemental New Drug Application in August 2026 seeking accelerated FDA approval for selinexor combined with ruxolitinib in myelofibrosis. The company will request priority review, and approval could make the treatment the first approved combination therapy in this setting. Karyopharm myelofibrosis sNDA announcement
• Piper Sandler maintained an “overweight” rating while lowering its price target to $7.00. The target still indicates substantial potential upside if Karyopharm’s pipeline programs succeed.
• HC Wainwright reaffirmed its “neutral” rating but cut its price target to $3.00 from $13.00, reflecting sharply reduced expectations after the endometrial-cancer update.
• Robert W. Baird downgraded KPTI from “outperform” to “neutral” and set a $3.00 price target, signaling a more cautious view despite implied upside from recent trading levels.
• An executive vice president sold 189 shares for approximately $1,342, reducing the executive’s position by only 0.20%; the small transaction is unlikely to materially change the investment outlook. SEC insider transaction filing
• Karyopharm’s Phase 3 XPORT-EC-042 trial failed to meet its primary progression-free-survival endpoint in endometrial cancer. Although median PFS favored selinexor by 5.3 months in the modified intent-to-treat population, the miss led the company to reduce investment in the program and refocus resources on myelofibrosis and multiple myeloma. Karyopharm XPORT-EC-042 trial results
• Pomerantz LLP announced an investigation into potential claims on behalf of Karyopharm investors, adding legal overhang following the sharp decline. Pomerantz investor investigation